$19.23
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing
Overview
52-week range
$9.54
$24
66% of range
Avg surprise (last 3)
-16.4%
Avg reaction (last 2)
-1.0%
0% positive
Latest IV / EM
96%
EM ±15.0% · $20 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.83 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.98 | $1.00 | +2.0% | +21.6% | -0.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-2.19 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.92 | $-1.43 | -34.3% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-1.25 | $-1.07 | -16.8% | — | -1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.83 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-14.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-141.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-26.83 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-140.73 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-204.00 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | — | — | — | $249,000 |
| Cost of revenue | — | — | — | — | $0 | — | — | $-714,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-32M | $-21M | — | $-19M | $-19M | $-15M | — | $-13M |
| Net income | $-36M | $-20M | — | $-31M | $-21M | $-13M | — | $23M |
| EPS (diluted) | $-0.83 | $-0.98 | — | $-2.19 | $-1.92 | $-1.25 | — | $-2.83 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85M | $25M | $16M | $27M | $42M | $125M | $135M | $82M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $408M | $89M | $105M | $114M | $115M | $127M | $139M | $86M |
| Total assets | $491M | $100M | $116M | $125M | $127M | $139M | $151M | $98M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $42M | $32M | $33M | $34M | $22M | $16M | $18M | $76M |
| Total equity | $449M | $68M | $83M | $92M | $105M | $123M | $133M | $21M |